ArticleInfection and drug resistance2026
Isavuconazole in Pediatric Invasive Fungal Infections: Outcomes and Therapeutic Drug Monitoring in a Chinese Multicenter Case Series.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Real-world evidence regarding the efficacy of isavuconazole (ISA) for pediatric invasive fungal infections (IFIs) remains scarce, particularly in Asia. Methods: This retrospective multicenter observational study (January 2022-June 2025) was conducted at four tertiary hospitals in central China. Children aged 1-17 years with IFI who received ISA for ≥7 days were included. Therapeutic drug monitoring (TDM) of trough concentrations (C Results: Ten children (median age, 6.5 years [range, 2 months-16 years]; 50% male) were enrolled. ISA was used as salvage therapy in 80% of patients due to failure or toxicity of prior antifungal agents. The median treatment duration was 43.5 days (range: 10-318 days). The initial median C Conclusion: This first Chinese multicenter pediatric series demonstrated the excellent efficacy and tolerability of ISA when combined with routine TDM and clinical pharmacist stewardship. It should be noted that our study has a small sample size, requiring further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.